In summary, endogenous expression of RAC1P29S in BRAF-driven melanoma produces a less melanocytic and more mesenchymal differentiation state and generates resistance to the BRAF inhibitor PLX4720, which can be substantially reversed by co-treatment with an SRF/MRTF inhibitor. The gene discussed is BRAF; the disease is melanoma.